Requip News and Research

RSS

Parkinson's disease medications could lead to impulse control disorders

Drugs commonly prescribed to treat Parkinson's disease have been linked to impulse control disorders such as pathological gambling, compulsive buying, hypersexuality and binge eating in some patients, report neurologists from Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

6 Apr 2016

Actavis receives FDA approval for Ropinirole ER Tablets

Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip XL.

19 May 2012

Parkinson's disease drugs may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

25 Mar 2011

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

GlaxoSmithKline is being sued this week by a French father-of-two, alleging the British pharmaceutical firm’s drug – Reqip (Ropirnirole) to treat Parkinson’s disease turned him into a gay sex and gambling addict. Parkinson’s disease is a seriously and progressively debilitating disease that leads to tremors, slowing of movements and ultimately total immobility.

1 Feb 2011

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.

9 Dec 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Save money wih generics

Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.

10 Dec 2008

FDA approves first generic versions of Requip (ropinirole hydrochloride)

The U.S. Food and Drug Administration has approved the first generic versions of Requip (ropinirole hydrochloride) tablets for the treatment of moderate to severe Restless Legs Syndrome.

9 May 2008

Requip significantly reduces periodic leg movements in patients with restless legs syndrome

New data published in the August issue of SLEEP shows that patients with primary Restless Legs Syndrome (RLS) and with periodic leg movements during sleep (PLMS), have fewer awakenings resulting from involuntary kicks when treated with GlaxoSmithKline's Requip (ropinirole HCl).

2 Aug 2004